A monofunctional Pt(II) complex combats triple negative breast cancer by triggering lysosome-dependent cell death.
Dalton Trans
; 53(8): 3808-3817, 2024 Feb 20.
Article
em En
| MEDLINE
| ID: mdl-38305380
ABSTRACT
Monofunctional Pt(II) complexes with potent efficacy to overcome the drawbacks of current platinum drugs represent a promising therapeutic approach for triple negative breast cancer (TNBC). A heterocyclic-ligated monofunctional Pt(II) complex PtL with a unique action of mode was designed and investigated. PtL induced DNA single-strand breaks and caused genomic instability in TNBC cells. Mechanism studies demonstrated that PtL disrupted lysosomal acidity and function, which in turn triggered lysosome-dependent cell death. Furthermore, PtL showed convincing suppression in the tube forming and cell migratory abilities against the metastatic potential of TNBC cells. The synthesis and investigation of PtL revealed its potential value as an anti-TNBC drug and extended the family of monofunctional Pt(II) complexes.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias de Mama Triplo Negativas
Limite:
Humans
Idioma:
En
Revista:
Dalton Trans
/
Dalton trans (2003. Online)
/
Dalton transactions (2003. Online)
Assunto da revista:
QUIMICA
Ano de publicação:
2024
Tipo de documento:
Article